Tango Therapeutics, Inc. (TNGX) income statement
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30126% above fair value
$21.89−0.22 (-1.00%)
Close on Nov 18, 2026Market cap $3.69BP/E –Yield –
Tango Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -253.4%
- Net margin
- -229.9%
- Return on equity, FY2025
- -37.2%
Financial strength
- Current ratio
- 50.82
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1702.3%
Valuation
- P/E ratio
- –
- Price to sales
- 68.59
- Price to book
- 3.60
- Dividend yield
- –
See a number that looks wrong?